Search results
Results from the WOW.Com Content Network
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Anti-cancer monoclonal antibodies can be targeted against malignant cells by several mechanisms. Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment of advanced malignancies. [18] In childhood lymphoma, phase I and II studies have found a positive effect of using antibody therapy. [19]
Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor type 4 (CCR4). [5] [7] It is given by injection into a vein. [5] [6] The most common side effects include rash, infusion-related reactions, fatigue, diarrhea, musculoskeletal pain, and upper respiratory tract ...
Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor as a treatment for pain via a novel mechanisms different from conventional pain-killer drugs. [1] Tanezumab was discovered and developed by Rinat Neuroscience [2] and was acquired by Pfizer in 2006.
Golimumab, sold under the brand name Simponi, is a human monoclonal antibody which is used as an immunosuppressive medication. [3] [5] Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule [6] and hence is a TNF inhibitor.
Monoclonal antibodies, when given early, can help prevent severe illness in high-risk patients. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 ...
Ocrelizumab is a humanized monoclonal antibody that binds to a CD20 epitope that overlaps partially with the epitope to which rituximab binds. [10] It has an immunoglobulin G1 with a variable region against human CD20, with a human-mouse monoclonal 2H7 γ1-chain, bound via disulfide links with human-mouse monoclonal 2H7 κ-chain in a dimer. [16]
Ofatumumab is a fully human anti-CD20 monoclonal antibody whose epitope is distinct from that of rituximab. [24] Ofatumumab binds to a distinct epitope on small and large extracellular loops of CD20. [ 25 ] [ 26 ] The CD20 antigen is expressed on solely B cell lymphocytes. [ 24 ]